Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Inclusion criteria include:
Exclusion criteria include:
Santa Teresa, California 95119, United States
South San Francisco, California 94080, United States
Honolulu, Hawaii 96826, United States
Effingham, Illinois 62401, United States
Lake Forest, Illinois 60045, United States
New Hyde Park, New York 11040, United States
Winston-Salem, North Carolina 27103, United States
Smyma, Tennessee 37167, United States
Buenos Aires, Buenos Aires C1181ACH, Argentina
Buenos Aires, Buenos Aires C1405CNF, Argentina
Buenos Aires, Buenos Aires C1405DCS, Argentina
Buenos Aires, Buenos Aires C1437JCP, Argentina
Buenos Aires, Buenos Aires, Argentina
Buenos Aires, Buenos Aires, Argentina
Capital Federal, Buenos Aires 1408, Argentina
Lindedreef, Antwerpen 2020, Belgium
Wilrijkstraat, Edegem 2650, Belgium
Herestraat, Leuven 49, Belgium
Bairro Bom Fim, Porto Alegre 90035-003, Brazil
Independencia, Santiago Metropolitan Santos Dumontt 999, Chile
Kyjevska 44, Pardubice 53203, Czechia
Doudlevecka 69, Plzen 301 31, Czechia
Unemocnice, Prague 12808, Czechia
Havlickovo Nabrezi 600, ZlÃn 76001, Czechia
Havlickovo Nabrezi, ZlÃn 76001, Czechia
Baross, H-1088, Hungary
Rakoczi, Hungary
Rakoczi, Hungary
Belfast, BT9 7AB, Ireland
HV Amsterdam, 1081, Netherlands
Die Wilgers X14, Pretoria 41, South Africa
Vall d'Hebron, Barcelona 119-129, Spain
Profesor Beltran Baguena, Valencia 46009, Spain
Scotland, Dundee DD1 9SY, United Kingdom